How much funding has EydisBio, Inc. raised?

EydisBio, Inc. has raised $6.7M in total funding, most recently a grant round.

Who are EydisBio, Inc.'s investors?

EydisBio, Inc.'s investors include National Institute of Health (NIH).

When was EydisBio, Inc. founded?

EydisBio, Inc. was founded in 2019.

Where is EydisBio, Inc. headquartered?

EydisBio, Inc. is headquartered in DURHAM, North Carolina, United States.

What industry is EydisBio, Inc. in?

EydisBio, Inc. operates in Biotech, Healthcare.

How many employees does EydisBio, Inc. have?

EydisBio, Inc. has 1-10 employees.

EydisBio, Inc.

Novel small molecule therapies for autoimmune and inflammatory diseases

DURHAM, United States · Founded 2019 · $6.7M raised

Biotech

Healthcare

Headquarters: DURHAM, North Carolina
Employees: 1–10
Founded: 2019
Business Model: B2B

Website: eydisbio.com
Total Funding: $6.7M
Last Round: $6.7M Grant
Rounds: 1

About

EydisBio develops highly selective small molecule kinase inhibitors for autoimmune and inflammatory diseases, leveraging its Universal Purinome Capture Platform (UPCP). The company's lead program targets TAK1 for conditions including rheumatoid arthritis, systemic sclerosis, and chronic pain. EydisBio spun out of Duke University's Haystead Lab in 2016 and has received FDA Orphan Drug Designation for its EYD-001 candidate.

Summary

EydisBio, Inc. is a Biotech company based in DURHAM, United States, founded in 2019. It has raised $6.7M in total across 1 round. Investors include National Institute of Health (NIH).